Showing results (521-530 of 1,104) with videos related to
Sort By:
Pageof 111
Journal of Medicinal Chemistry|February 3, 2015
Discovery of AZD3147: a potent, selective dual inhibitor of mTORC1 and mTORC2Kurt G Pike, Jeff Morris, Linette Ruston, et al.Journal of Medicinal Chemistry|December 19, 2019
The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) InhibitorFrederick W Goldberg, M Raymond V Finlay, Attilla K T Ting, et al.JCO Precision Oncology|February 16, 2022
Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase InhibitorsMorten Lapin, Helen J Huang, Sharmeen Chagani, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2018
Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung CancerCaroline E McCoach, Collin M Blakely, Kimberly C Banks, et al.Journal of Medicinal Chemistry|February 20, 2015
Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activationJon J G Winter, Malcolm Anderson, Kevin Blades, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 3, 2021
Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLCVincent K Lam, Jianjun Zhang, Carol C Wu, et al.ACS Medicinal Chemistry Letters|August 18, 2022
Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8H-purin-8-one Inhibitors of DNA-PKFrederick W Goldberg, Attilla K T Ting, David Beattie, et al.Pacing and Clinical Electrophysiology : PACE|December 20, 2016
Evaluation of a Unique Defibrillation Unit with Dual-Vector Biphasic Waveform Capabilities: Towards a Miniaturized DefibrillatorHideo Okamura, Christopher V Desimone, Ammar M Killu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2024
Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent TreatmentAparna R Parikh, Bryant H Chee, Jill Tsai, et al.JCO Precision Oncology|October 5, 2020
Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA AssayKatherine Clifton, Thereasa A Rich, Christine Parseghian, et al.Pageof 111